Sunday, February 8, 2026
StockstToday.com Logo
  • Home
  • Tech & Software
  • Earnings
  • Analysis
  • Trading & Momentum
  • Cryptocurrency
  • Banking & Insurance
  • AI & Quantum Computing
No Result
View All Result
  • Home
  • Tech & Software
  • Earnings
  • Analysis
  • Trading & Momentum
  • Cryptocurrency
  • Banking & Insurance
  • AI & Quantum Computing
No Result
View All Result
StocksToday.com Logo
No Result
View All Result
Home Breaking News

Chatham Lodging Trust Exceeds Q1 2024 Financial Projections

Elaine Mendonca by Elaine Mendonca
February 27, 2024
in Breaking News
0
0
SHARES
8
VIEWS
Share on FacebookShare on Twitter

Chatham Lodging Trust has projected that their adjusted FFO per share for Q1 of 2024 will range from $0.10 to $0.14. However, when the actual numbers came in, it surpassed expectations with a reported $0.46 per share. This unexpected outcome highlights a notable disparity between the company’s forecasts and the real financial results for the initial quarter of 2024.

Chatham Lodging Trust (CLDT) Stock Market Update: February 27, 2024

On February 27, 2024, Chatham Lodging Trust (CLDT) had a mixed performance in the stock market. The stock closed at $10.26, which was a decrease of $0.17 or 1.63% from the previous trading day. Despite this drop, CLDT is still trading in the middle of its 52-week range and above its 200-day simple moving average, indicating some stability in its price momentum.

Investors and analysts will continue to keep an eye on CLDT’s performance in the coming days to see if the stock can regain its momentum or if it will continue to experience fluctuations. As always, it is important for investors to conduct thorough research and analysis before making any investment decisions, especially in a volatile market environment.

CLDT Stock Performance Analysis: Revenue and Net Income Growth in 2024

On February 27, 2024, CLDT stock experienced mixed performances based on the financial data provided by CNN Money. The company reported a total revenue of $294.85 million over the past year, which marked a significant increase of 44.55% compared to the previous year. However, the total revenue remained flat since the last quarter, standing at $86.74 million.

In terms of net income, CLDT reported a net income of $9.78 million over the past year, representing a substantial increase of 153.12% compared to the previous year. However, the net income decreased by 19.9% since the last quarter, reaching $7.30 million.

Earnings per share (EPS) also showed mixed performances for CLDT stock. The company reported an EPS of $0.04 over the past year, marking an increase of 108.06% compared to the previous year. However, the EPS decreased by 25.48% since the last quarter, standing at $0.11.

Overall, CLDT stock showed strong growth in total revenue and net income compared to the previous year. However, the company experienced a slight decline in net income and EPS since the last quarter. Investors may want to closely monitor CLDT stock performances and financial reports to assess the company’s future growth potential and investment opportunities.

Tags: CLDT
Elaine Mendonca

Elaine Mendonca

Related Posts

NFT projects
Breaking News

The Impact of TikToks Fate on USChina Relations and American Tech Giants

March 16, 2024
Businesses finance
Breaking News

Blackstone Strategic Credit 2027 Term Fund BGB Announces Monthly Dividend of 93 Cents per Share

March 15, 2024
Healthcare-sector
Breaking News

Analyzing Short Interest in Molina Healthcare Inc MOH

March 15, 2024
Next Post

Perrigo Reports Strong Earnings Growth in Fourth Quarter 2024

Wind Farms: How Strategic Acquisitions Amplify the Impact of Green Energy Players

Analyzing Atlas Energy Solutions Q4 2023 Financial Results

Real Estate Investment Markets and money

Easterly Government Properties Announces Quarterly Financial Results for Q1 2024

Recommended

Biotechnology Stock Exchange

Analysts Bullish on Dynatrace with Price Targets on the Rise

2 years ago
The Trade Desk Stock

The Trade Desk Faces Mounting Pressure as Amazon Strikes Netflix Deal

5 months ago

Analyst Reaffirms Buy Rating on International Seaways with 66 Price Target

2 years ago
Biotechnology Stock Bull Market

KeyBanc Analyst Raises Price Target and Maintains Overweight Rating on Repligen NASDAQ RGEN

2 years ago

Categories

  • AI & Quantum Computing
  • Analysis
  • Analyst Ratings
  • Asian Markets
  • Automotive & E-Mobility
  • Banking & Insurance
  • Bitcoin
  • Blockchain
  • Bonds
  • Breaking News
  • Business & Industry Trends
  • Cannabis
  • Chemicals
  • Commodities
  • Consumer & Luxury
  • Crypto Stocks
  • Cryptocurrency
  • Cyber Security
  • DAX
  • Defense & Aerospace
  • Dividends
  • Dow Jones
  • E-Commerce
  • Earnings
  • Emerging Markets
  • Energy & Oil
  • ETF
  • Ethereum & Altcoins
  • European Markets
  • Forex
  • Gaming & Metaverse
  • Gold & Precious Metals
  • Healthcare
  • Hydrogen
  • Index
  • Industrial
  • Insider Trading
  • IPOs
  • Market Commentary
  • Market News
  • MDAX & SDAX
  • Mergers & Acquisitions
  • Nasdaq
  • Newsletter
  • Penny Stocks
  • Pharma & Biotech
  • Real Estate & REITs
  • Renewable Energy
  • S&P 500
  • Semiconductors
  • Space
  • Stock Picks
  • Stock Targets
  • Stocks
  • TecDAX
  • Tech & Software
  • Telecommunications
  • Trading & Momentum
  • Turnaround
  • Uncategorized
  • Value & Growth

Topics

Adobe Alibaba Alphabet Amazon AMD Apple ASML BioNTech Bitcoin Broadcom Coca-Cola Coinbase D-Wave Quantum Eli Lilly Fiserv IBM Intel Kraft Heinz Marvell Technology META Micron Microsoft MP Materials MSCI World ETF Newmont Mining NIO Novo Nordisk Nvidia Ocugen Opendoor Oracle Palantir PayPal Plug Power QuantumScape Robinhood Rocket Lab USA Strategy Super Micro Computer Synopsys Tesla Tilray Unitedhealth Uranium Energy Viking Therapeutics
No Result
View All Result

Highlights

Sanofi Completes Vigil Neuroscience Acquisition, Eyes Alzheimer’s Therapy

Repay Holdings: Annual Report to Test Strategic Refinancing Success

Amazon’s $200 Billion Penalty, The Bad News Rally, and A Cloud Divorce

Graftech Shares Plunge on Bleak Quarterly Results

Potbelly Accelerates Northeast Growth with New Jersey Franchise Push

Conduent Faces Mounting Fallout from Major Data Breach Ahead of Earnings

Trending

Puma Biotechnology Stock
Earnings

Puma Biotechnology Sets Date for Full-Year Financial Disclosure

by Jackson Burston
February 8, 2026
0

Investor attention is now firmly fixed on February 26, 2026, as Puma Biotechnology prepares to release its...

Quanterix Stock

Quanterix Seeks FDA Clearance for Groundbreaking Alzheimer’s Blood Test

February 8, 2026
Design Therapeutics Stock

Design Therapeutics Approaches Key Clinical Milestones with Ample Funding

February 7, 2026
Vigil Neuroscience Stock

Sanofi Completes Vigil Neuroscience Acquisition, Eyes Alzheimer’s Therapy

February 7, 2026
Repay Holdings Stock

Repay Holdings: Annual Report to Test Strategic Refinancing Success

February 7, 2026

StocksToday.com is your one-stop destination for the latest stock news and analysis. We provide in-depth coverage of the stock market, including market news, company news, sector news, IPO news, investment strategies, personal finance, international markets, and more.

Follow us on social media:

Recent News

  • Puma Biotechnology Sets Date for Full-Year Financial Disclosure
  • Quanterix Seeks FDA Clearance for Groundbreaking Alzheimer’s Blood Test
  • Design Therapeutics Approaches Key Clinical Milestones with Ample Funding

Category

  • About
  • Advertise
  • Careers
  • Contact
  • Imprint
  • Privacy Policy
  • Terms of Service

© 2023 StocksToday.com

No Result
View All Result
  • Home
  • Tech & Software
  • Earnings
  • Analysis
  • Trading & Momentum
  • Cryptocurrency
  • Banking & Insurance
  • AI & Quantum Computing

© 2023 StocksToday.com